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Interventions
The antifungal treatments were voriconazole and lipid formulations of amphotericin B (L-AMB) used as first line therapy, and caspofungin and amphotericin B desoxycholate (D-AMB) used as second-line therapy. These treatments were used in combination or sequentially forming a total of seven treatment strategies, which were: Voriconazole followed by caspofungin; Voriconazole followed by D-AMB; Voriconazole followed by L-AMB; Voriconazole followed by L-AMB plus caspofungin; L-AMB followed by voriconazole; L-AMB followed by caspofungin; and L-AMB followed by voriconazole plus caspofungin.
Location/setting
Netherlands/secondary care.
Methods

Analytical approach:
A decision analytic model (decision tree) was constructed in order to compare the cost-effectiveness of the management strategies. The time horizon of the analysis was 12 weeks and the authors stated that the hospital perspective was adopted.
Effectiveness data:
Most of the effectiveness data were obtained from a literature review. Where data were unavailable, estimates were based on authors' assumptions derived by consensus. The criteria applied for the selection of the estimates, the process used to identify the data, and the sources searched were reported. The main clinical parameter was patient survival 12 weeks after initiating antifungal therapy.
